financetom
Business
financetom
/
Business
/
Photronics Fiscal Q2 Non-GAAP Earnings, Revenue Fall; New CEO Named
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Photronics Fiscal Q2 Non-GAAP Earnings, Revenue Fall; New CEO Named
May 28, 2025 4:54 AM

07:30 AM EDT, 05/28/2025 (MT Newswires) -- Photronics ( PLAB ) reported fiscal Q2 non-GAAP net income Wednesday of $0.40 per diluted share, down from $0.46 a year earlier.

Two analysts polled by FactSet expected $0.49.

Revenue for the quarter ended May 4 was $211 million, down from $217 million a year earlier.

Two analysts surveyed by FactSet expected $212.1 million.

The company said it expects fiscal Q3 non-GAAP EPS of $0.35 to $0.41 on revenue of $200 million to $208 million. Two analysts surveyed by FactSet expect $0.50 and $219.8 million, respectively.

Photronics ( PLAB ) said it has appointed Chairman George Macricostas as chief executive, effective immediately, replacing Frank Lee, who has stepped down from the role and intends to retire in "the next year or two."

The company's shares were down 5.2% in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Natural Gas Eases Early as the Heat Dome Cools
Natural Gas Eases Early as the Heat Dome Cools
Jun 24, 2024
09:16 AM EDT, 06/24/2024 (MT Newswires) -- Natural gas prices eased early on Monday as a heat dome that pushed temperatures in the Upper Midwest and Northeast to record highs last week and raised air-conditioning demand abated. Gas for July delivery was last seen down US$0.02 to US$2.69 per million British thermal units. The drop comes as temperatures in northern...
Altimmune Stock Is Rising Monday: What's Driving The Action?
Altimmune Stock Is Rising Monday: What's Driving The Action?
Jun 24, 2024
Altimmune Inc ( ALT ) shares are trading higher Monday after the company announced data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide. What Happened: Altimmune ( ALT ) said it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, including the results of a recently completed body composition analysis at the American Diabetes Association’s...
Evolus Completes FDA Premarket Approval Submission for Evolysse Dermal Fillers for 'Smile Lines'
Evolus Completes FDA Premarket Approval Submission for Evolysse Dermal Fillers for 'Smile Lines'
Jun 24, 2024
09:03 AM EDT, 06/24/2024 (MT Newswires) -- Evolus ( EOLS ) said Monday it submitted the final part of its premarket approval application to the US Food and Drug Administration for its Evolysse dermal filler products for nasolabial folds, also known as smile lines. The application covers Evolysse Lift and its softer alternative Evolysse Smooth, Evolus ( EOLS ) said,...
Eos Energy Receives $315.5 Million Investment From Cerberus
Eos Energy Receives $315.5 Million Investment From Cerberus
Jun 24, 2024
09:15 AM EDT, 06/24/2024 (MT Newswires) -- Eos Energy Enterprises ( EOSE ) said Monday that an affiliate of Cerberus Capital has invested up to $315.5 million to enable Eos Energy ( EOSE ) to restructure existing debt and expand operations. The investment is structured as a $210.5 million delayed draw term loan contingent on operational milestones through April 2025...
Copyright 2023-2025 - www.financetom.com All Rights Reserved